摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,6-二羟基-4-甲基苯乙酮 | 1634-34-0

中文名称
2,6-二羟基-4-甲基苯乙酮
中文别名
3,5-二羟基-4-乙酰甲苯;4-乙酰基-3,5-二羟基甲苯;3.5-二羟基-4-乙酰甲苯
英文名称
2',6'-dihydroxy-4'-methylacetophenone
英文别名
2,6-Dihydroxy-4-methyl-acetophenon;3,5-dihydroxy-4-acetyltoluene;2-acetylorcinol;1-(2,6-dihydroxy-4-methylphenyl)ethanone;4-methyl-2,6-dihydroxyacetophenone
2,6-二羟基-4-甲基苯乙酮化学式
CAS
1634-34-0
化学式
C9H10O3
mdl
MFCD06656138
分子量
166.177
InChiKey
CUYUORWXJSURNV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    142-144 °C
  • 沸点:
    288.7±35.0 °C(Predicted)
  • 密度:
    1.239±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2914501900
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319
  • 储存条件:
    室温且干燥

SDS

SDS:f921fb8254ea60671d8082690f2721d9
查看

制备方法与用途

化学性质:白色至淡黄色针状结晶,熔点为142-146℃。肟衍生物的熔点为211-212℃。该物质微溶于水、二硫化碳和苯,并能溶解于醇、醚和乙酸中。它容易溶解在氨水及碱性溶液中。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,6-二羟基-4-甲基苯乙酮 在 platinum on activated charcoal 2,4,6-三甲基吡啶4-二甲氨基吡啶氢氧化钾苄基三丁基氯化铵potassium carbonate 作用下, 以 乙醇二氯甲烷氯仿N,N-二甲基甲酰胺 为溶剂, 反应 64.67h, 生成 Carbonic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester ethyl ester
    参考文献:
    名称:
    Na+-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4‘-Dehydroxyphlorizin Derivatives Substituted on the B Ring
    摘要:
    In our studies of Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents, a series of novel 4'-dehydroxyphlorizin derivatives substituted on the B ring was prepared and their effects on urinary glucose excretion were evaluated in rats. Introduction of only a small alkyl group at the 4'-position increased the activity, and 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-beta-D-glucopyranoside (4) showed the most potent effect. To overcome hydrolysis of compound 4 by beta-glucosidase in the digestive tract, the OH groups on the glucose moiety of compound 4 were modified. Three prodrugs (5, 42, and 55) were more potent than the parent compound 4 by oral administration, and finally 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl-beta-D-glucopyranoside) (5) was selected as a new promising candidate. Compound 5 was metabolized mainly by liver esterase to the active form (4), which was about 10 times more potent than 5 in inhibiting SGLT. In oral glucose tolerance test in db/db mice, compound 5 dose-dependently suppressed the elevation of glucose levels. Single administration of 5 reduced hyperglycemia concurrently with increase of glucose excretion into urine in diabetic KK-A(y) mice. Furthermore, compound 5 suppressed the elevation of blood glucose levels but did not lower it below the normal level even in fasted conditions in KK-A(y) mice. Additionally, long-term treatment with 5 dose-dependently reduced hyperglycemia and HbA1c in KK-A(y) mice. These pharmacological data strongly suggest that compound 5 has a therapeutic potential in the treatment of NIDDM.
    DOI:
    10.1021/jm990175n
  • 作为产物:
    描述:
    3,5-二羟基甲苯吡啶三氯化铝 作用下, 以 氯苯 为溶剂, 生成 2,6-二羟基-4-甲基苯乙酮
    参考文献:
    名称:
    糖基化的二氢查耳酮作为有效的和选择性的钠葡萄糖共转运蛋白2(SGLT2)抑制剂。
    摘要:
    合成了一系列葡萄糖缀合物,并测试了其对SGLT1和SGLT2的抑制作用。核心结构衍生自化合物1a。化合物1a中苯并呋喃部分和苯环的4'-取代基的修饰改善了对SGLT2的选择性。在代谢稳定性和体内功效研究中,将所选化合物与1a进行了比较。
    DOI:
    10.1016/j.bmcl.2004.07.082
点击查看最新优质反应信息

文献信息

  • HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS
    申请人:Alvaro Giuseppe
    公开号:US20130267510A1
    公开(公告)日:2013-10-10
    The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    该发明提供了化合物的公式(I):所述化合物是Kv3通道的抑制剂,可用于预防或治疗相关疾病。
  • 具有抑制结核分枝杆菌活性的新型二苯甲基 类化合物
    申请人:清华大学
    公开号:CN109293493B
    公开(公告)日:2021-08-03
    本发明涉及具有抑制结核分枝杆菌活性的新型二苯甲基类衍生物及其制备方法,特别是具有抑制复制性和非复制性结核分枝杆菌活性的新型二苯甲基类衍生物及其制备方法。具体地,本发明涉及式(I)所示的化合物或其所有可能的异构体、前药、可药用盐、溶剂合物或水合物,其中各变量如说明书所述。还涉及本发明化合物的制备方法、包含本发明化合物的药物组合物、以及本发明化合物在制备抗结核分枝杆菌感染引起的疾病的药物中的用途。
  • Rapid Synthesis of Polyprenylated Acylphloroglucinol Analogs via Dearomative Conjunctive Allylic Annulation
    作者:Alexander J. Grenning、Jonathan H. Boyce、John A. Porco
    DOI:10.1021/ja5060302
    日期:2014.8.20
    Polyprenylated acylphloroglucinols (PPAPs) are structurally complex natural products with promising biological activities. Herein, we present a biosynthesis-inspired, diversity-oriented synthesis approach for rapid construction of PPAP analogs via double decarboxylative allylation (DcA) of acylphloroglucinol scaffolds to access allyl-desoxyhumulones followed by dearomative conjunctive allylic alkylation
    聚异戊二烯化酰基间苯三酚 (PPAPs) 是结构复杂的天然产物,具有良好的生物活性。在此,我们提出了一种受生物合成启发、面向多样性的合成方法,通过酰基间苯三酚支架的双脱羧烯丙基化 (DcA) 获得烯丙基-脱氧葎草酮,然后进行脱芳基连接烯丙基烷基化 (DCAA),从而快速构建 PPAP 类似物。
  • [EN] HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOÏNE UTILES EN TANT QU'INHIBITEURS DE KV3
    申请人:AUTIFONY THERAPEUTICS LTD
    公开号:WO2012076877A1
    公开(公告)日:2012-06-14
    The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    该发明提供了化合物的公式(I):所述化合物是Kv3通道的抑制剂,可用于预防或治疗相关疾病。
  • Piperazine derivatives
    申请人:Middleton Stuart Donald
    公开号:US20050043300A1
    公开(公告)日:2005-02-24
    This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R 1 to R 5 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives. The compounds of the present invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, or AIDS.
    这项发明涉及一种具有化学式(I)的化合物 或其药用可接受的盐、溶剂合物或衍生物,其中R 1 至R 5 在描述中有定义,并涉及其制备方法、制备中使用的中间体、含有它们的组合物以及这些衍生物的用途。 本发明的化合物抑制gp120与CD4的相互作用,因此在治疗HIV、与HIV有遗传关系的逆转录病毒感染或艾滋病方面有用。
查看更多